Summit Therapeutics Inc (SMMT) said Monday it will collaborate with Pfizer (PFE) on a set of clinical trials to evaluate ivonescimab, its investigational drug, in combination with several Pfizer antibody drug conjugates to treat multiple solid tumors.
Financial terms were not disclosed.
Under the agreement, Summit will provide ivonescimab, while Pfizer will conduct the studies, which are planned to begin mid-2025 and will be overseen by both companies.
Each study will evaluate ivonescimab in combination with one of Pfizer's vedotin ADCs in distinct solid tumor settings to determine the safety profile and potential tumor-fighting ability of the combinations.
Summit shares were up 5% in recent premarket activity.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。